Cancer Trials: Beware Of ‘Digital Exhaust’ When Planning Clinical Outcome Assessments
Executive Summary
Patient data gathered through wearables and sensors can complement traditional patient-reported outcome assessments, but continuous digital monitoring runs the risk of overburdening clinical trial participants.
You may also be interested in...
Standardization Of Patient-Focused Core Clinical Outcomes Could Enable Labeling Comparisons
US FDA’s Theresa Mullin envisions having a national catalog of standard core clinical outcomes assessment measures that could apply to every disease area.
Cancer Trials: Patient-Reported Outcomes Should Measure Five Core Concepts, US FDA Says
Heterogeneity in PRO assessment strategies has lessened the regulatory utility of such data from cancer trials, the agency says; new draft guidance recommends systematic assessment of a core set of PROs in registrational studies using fit-for-purpose tools and includes examples of acceptable instruments.
Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits
Reduction in the risk of hypoglycemia level 2 and 3 events, along with either a reduction or maintenance of an acceptable hemoglobin A1C, is a clinically relevant efficacy endpoint for drug development in Types 1 and 2 diabetes, FDA states in new draft guidance.